Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications
04:36pm, Thursday, 03'rd Mar 2022 Benzinga
Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO ) have updated their existing strategic collaboration to develop, manufacture, and commercialize infigratinib for oncology indications. Under the amended and restated agreement terms, Helsinn will gain an exclusive license to commercialize infigratinib … Full story available on Benzinga.com
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
12:30pm, Thursday, 03'rd Mar 2022 GlobeNewswire
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize I nfigratinib in Oncology Indications in the U . S .
BridgeBio Pharma (BBIO) Presents At Global Healthcare Virtual Conference - Slideshow
10:49pm, Friday, 25'th Feb 2022 Seeking Alpha
BridgeBio Pharma GAAP EPS of -$1.01 misses by $0.16, revenue of $12.89M misses by $8.69M
12:57pm, Thursday, 24'th Feb 2022 Seeking Alpha
BridgeBio Pharma press release (BBIO): Q4 GAAP EPS of -$1.01 misses by $0.16.Revenue of $12.89M (+10641.7% Y/Y) misses by $8.69M.Shares -4.5% PM.
12 biotech stocks to consider buying now as prospects for the sector brighten this year
04:53pm, Sunday, 06'th Feb 2022
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
BridgeBio begins dosing of gene therapy in phase 1/2 trial for adrenal gland disorder
01:33pm, Thursday, 27'th Jan 2022 Seeking Alpha
BridgeBio Pharma (BBIO) said the first patient was dosed in a phase 1/2 trial, dubbed ADventure, evaluating its gene therapy BBP-631 to treat adults with classic congenital…
Andreas Halvorsen Gets in on Amylyx Pharmaceuticals' IPO
12:59pm, Tuesday, 25'th Jan 2022
Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.
BridgeBio Pharma (BBIO) Investor Presentation - Slideshow
05:11pm, Monday, 24'th Jan 2022 Seeking AlphaBridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study
03:24pm, Friday, 14'th Jan 2022
BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.
Buying BridgeBio Pharma On The Drop After Phase 3 Amyloidosis Failure
05:52am, Tuesday, 04'th Jan 2022
Buying BridgeBio Pharma On The Drop After Phase 3 Amyloidosis Failure
BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?
04:39am, Monday, 03'rd Jan 2022
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incre
Is BridgeBio Pharma Stock a Buy on the Dip?
05:41am, Wednesday, 29'th Dec 2021
This company's market value plunged by around $8 billion in 2021, leading contrarian investors to suspect a bargain opportunity.
Why BridgeBio Pharma Shares Are Rising
12:19pm, Tuesday, 28'th Dec 2021
BridgeBio Pharma Inc (NASDAQ: BBIO) is trading higher Tuesday as the stock rebounds after falling on Monday. BridgeBio Pharma shares traded lower Monday after the company announced that its Phase 3
BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure
10:44am, Tuesday, 28'th Dec 2021
BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend.
Why Bridgebio Pharma Stock Is Imploding on Monday
01:16pm, Monday, 27'th Dec 2021
Investors are more than a little disappointed with a phase 3 clinical trial failure.
